Megalin‐related mechanism of hemolysis‐induced acute kidney injury and the therapeutic strategy

Abstract

AbstractHemolysis‐induced acute kidney injury (AKI) is attributed to heme‐mediated proximal tubule epithelial cell (PTEC) injury and tubular cast formation due to intratubular protein condensation. Megalin is a multiligand endocytic receptor for proteins, peptides, and drugs in PTECs and mediates the uptake of free hemoglobin and the heme‐scavenging protein α1‐microglobulin. However, understanding of how megalin is involved in the development of hemolysis‐induced AKI remains elusive. Here, we investigated the megalin‐related pathogenesis of hemolysis‐induced AKI and a therapeutic strategy using cilastatin, a megalin blocker. A phenylhydrazine‐induced hemolysis model developed in kidney‐specific mosaic megalin knockout (MegKO) mice confirmed megalin‐dependent PTEC injury revealed by the co‐expression of kidney injury molecule‐1 (KIM‐1). In the hemolysis model in kidney‐specific conditional MegKO mice, the uptake of hemoglobin and α1‐microglobulin as well as KIM‐1 expression in PTECs was suppressed, but tubular cast formation was augmented, likely due to the nonselective inhibition of protein reabsorption in PTECs. Quartz crystal microbalance analysis revealed that cilastatin suppressed the binding of megalin with hemoglobin and α1‐microglobulin. Cilastatin also inhibited the specific uptake of fluorescent hemoglobin by megalin‐expressing rat yolk sac tumor‐derived L2 cells. In a mouse model of hemolysis‐induced AKI, repeated cilastatin administration suppressed PTEC injury by inhibiting the uptake of hemoglobin and α1‐microglobulin and also prevented cast formation. Hemopexin, another heme‐scavenging protein, was also found to be a novel ligand of megalin, and its binding to megalin and uptake by PTECs in the hemolysis model were suppressed by cilastatin. Mass spectrometry‐based semiquantitative analysis of urinary proteins in cilastatin‐treated C57BL/6J mice indicated that cilastatin suppressed the reabsorption of a limited number of megalin ligands in PTECs, including α1‐microglobulin and hemopexin. Collectively, cilastatin‐mediated selective megalin blockade is an effective therapeutic strategy to prevent both heme‐mediated PTEC injury and cast formation in hemolysis‐induced AKI. © 2024 The Pathological Society of Great Britain and Ireland.